These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34052236)

  • 1. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine".
    Schwotzer N; Kissling S; Fakhouri F
    Kidney Int; 2021 Aug; 100(2):458-459. PubMed ID: 34052236
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Komaba H; Wada T; Fukagawa M
    Am J Kidney Dis; 2021 Sep; 78(3):469-470. PubMed ID: 34023417
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.
    Kervella D; Jacquemont L; Chapelet-Debout A; Deltombe C; Ville S
    Kidney Int; 2021 Aug; 100(2):457-458. PubMed ID: 33964312
    [No Abstract]   [Full Text] [Related]  

  • 4. Relapse of minimal change disease and inactivated SARS-CoV-2 vaccination.
    Sriwijitalai W; Wiwanitkit V
    Int Urol Nephrol; 2022 Dec; 54(12):3299. PubMed ID: 35727465
    [No Abstract]   [Full Text] [Related]  

  • 5. Relapse of minimal change disease after inactivated SARS-CoV-2 vaccination: case report.
    Özkan G; Bayrakçı N; Karabağ S; Güzel EÇ; Ulusoy S
    Int Urol Nephrol; 2022 Apr; 54(4):971-972. PubMed ID: 34181144
    [No Abstract]   [Full Text] [Related]  

  • 6. A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose.
    Mochizuki RI; Takahashi N; Ikenouchi K; Shoda W; Kuyama T; Takahashi D
    CEN Case Rep; 2022 Nov; 11(4):477-481. PubMed ID: 35435622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Maas RJ; Gianotten S; van der Meijden WAG
    Am J Kidney Dis; 2021 Aug; 78(2):312. PubMed ID: 33992727
    [No Abstract]   [Full Text] [Related]  

  • 8. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor.
    Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
    Holzworth A; Couchot P; Cruz-Knight W; Brucculeri M
    Kidney Int; 2021 Aug; 100(2):463-464. PubMed ID: 34048824
    [No Abstract]   [Full Text] [Related]  

  • 10. Minimal change disease following vaccination for SARS-CoV-2.
    Mancianti N; Guarnieri A; Tripodi S; Salvo DP; Garosi G
    J Nephrol; 2021 Aug; 34(4):1039-1040. PubMed ID: 34143368
    [No Abstract]   [Full Text] [Related]  

  • 11. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine.
    Morlidge C; El-Kateb S; Jeevaratnam P; Thompson B
    Kidney Int; 2021 Aug; 100(2):459. PubMed ID: 34119512
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases.
    Hartley JL; Bailey N; Sharma A; Shawki H
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35246429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal change disease following the Moderna COVID-19 vaccine: first case report.
    Thappy S; Thalappil SR; Abbarh S; Al-Mashdali A; Akhtar M; Alkadi MM
    BMC Nephrol; 2021 Nov; 22(1):376. PubMed ID: 34763669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of Minimal Change Disease Following mRNA COVID-19 Vaccination.
    Pirzadeh A; Emami S; Zuckerman JE; Nobakht N
    Am J Case Rep; 2023 Nov; 24():e941621. PubMed ID: 37941318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal change disease and acute interstitial nephritis following SARS-CoV-2 BNT162b2 vaccination.
    Jongvilaikasem P; Rianthavorn P
    Pediatr Nephrol; 2022 Jun; 37(6):1419-1421. PubMed ID: 35132446
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine.
    Tuschen K; Bräsen JH; Schmitz J; Vischedyk M; Weidemann A
    Kidney Int; 2021 Oct; 100(4):941-944. PubMed ID: 34352310
    [No Abstract]   [Full Text] [Related]  

  • 19. Relapse rate in children with nephrotic syndrome during the SARS-CoV-2 pandemic.
    Chiodini B; Bellotti AS; Morello W; Bulgaro C; Farella I; Giordano M; Montini G; Ismaili K; Wissing KM
    Pediatr Nephrol; 2023 Apr; 38(4):1139-1146. PubMed ID: 35976441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
    Fornaro M; Venerito V; Iannone F; Cacciapaglia F
    J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.